Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RMD 
ResMed Inc (RMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: RMD (1-star) is a SELL. SELL since 5 days. Simulated Profits (16.50%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
19 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $291.86
1 Year Target Price $291.86
| 8 | Strong Buy |
| 4 | Buy |
| 6 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -21.93% | Avg. Invested days 36 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 39.55B USD | Price to earnings Ratio 28.41 | 1Y Target Price 291.86 |
Price to earnings Ratio 28.41 | 1Y Target Price 291.86 | ||
Volume (30-day avg) 19 | Beta 0.85 | 52 Weeks Range 199.07 - 293.81 | Updated Date 09/15/2025 |
52 Weeks Range 199.07 - 293.81 | Updated Date 09/15/2025 | ||
Dividends yield (FY) 0.77% | Basic EPS (TTM) 9.51 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 27.22% | Operating Margin (TTM) 33.87% |
Management Effectiveness
Return on Assets (TTM) 14.02% | Return on Equity (TTM) 25.86% |
Valuation
Trailing PE 28.41 | Forward PE 25.32 | Enterprise Value 39194867607 | Price to Sales(TTM) 7.69 |
Enterprise Value 39194867607 | Price to Sales(TTM) 7.69 | ||
Enterprise Value to Revenue 7.62 | Enterprise Value to EBITDA 20.38 | Shares Outstanding 146415008 | Shares Floating 145477784 |
Shares Outstanding 146415008 | Shares Floating 145477784 | ||
Percent Insiders 0.79 | Percent Institutions 64.76 |
Upturn AI SWOT
ResMed Inc
Company Overview
History and Background
ResMed Inc. was founded in 1989, originating from Baxter Healthcare. It focuses on developing, manufacturing, and distributing medical devices for respiratory disorders, primarily sleep apnea, COPD, and other chronic diseases. Over time, ResMed has grown through product innovation and strategic acquisitions to become a global leader in its field.
Core Business Areas
- Sleep and Respiratory Care: ResMed's core segment offering CPAP and APAP devices, masks, humidifiers, and related accessories for treating sleep apnea and respiratory insufficiency.
- Software as a Service (SaaS): Provides cloud-based software platforms for healthcare providers to manage patient data, streamline workflows, and improve patient outcomes, acquired through acquisitions like Brightree and MatrixCare.
Leadership and Structure
ResMed is led by CEO Michael Farrell. The company has a hierarchical structure with functional departments like R&D, Sales & Marketing, Operations, and Finance, all reporting to the executive leadership team and ultimately to the Board of Directors.
Top Products and Market Share
Key Offerings
- AirSense 11: AirSense 11 is a CPAP machine used for treating sleep apnea. It features personalized therapy options, remote monitoring capabilities, and a user-friendly design. Competitors include Philips (though currently constrained), Fisher & Paykel, and various Chinese manufacturers. Market share estimates vary, but ResMed holds a significant portion of the CPAP market. No specific revenue numbers for this single product are publicly broken out.
- AirFit Masks: ResMed's AirFit mask series includes various nasal, full-face, and nasal pillow mask options designed for comfort and effective therapy. Competitors include Philips (currently constrained), Fisher & Paykel, and many smaller mask manufacturers. ResMed holds a significant portion of the mask market. No specific revenue numbers for this single product are publicly broken out.
- Brightree: Brightree is a cloud-based software solution for home medical equipment (HME) providers and other post-acute care organizations. Competitors include WellSky, Netsmart, and numerous smaller players. ResMed acquired Brightree to expand its SaaS offerings. No specific revenue numbers for this single product are publicly broken out.
Market Dynamics
Industry Overview
The respiratory care market is driven by an aging population, increasing prevalence of sleep apnea and COPD, growing awareness of respiratory disorders, and technological advancements in medical devices. The industry is also impacted by reimbursement policies and regulatory requirements.
Positioning
ResMed is a leading player in the sleep apnea and respiratory care market, known for its innovative products, strong brand reputation, and global presence. The company benefits from its established relationships with healthcare providers and its growing SaaS business.
Total Addressable Market (TAM)
The total addressable market for sleep apnea devices and related software/services is estimated to be in the tens of billions of dollars globally. ResMed, with its leading market position, is well-positioned to capture a significant portion of this market. Specific TAM estimates vary based on market reports and analysis.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Innovative product portfolio
- Global presence and distribution network
- Growing SaaS business
- Strong R&D capabilities
Weaknesses
- Dependence on reimbursement policies
- Exposure to product recalls and regulatory risks
- Competition from lower-cost manufacturers
- Potential integration challenges with acquisitions
Opportunities
- Expanding into emerging markets
- Developing new products and therapies for respiratory disorders
- Leveraging digital health technologies to improve patient outcomes
- Acquiring complementary businesses
- Increasing penetration of home healthcare
Threats
- Intense competition
- Changes in reimbursement policies
- Product recalls and safety concerns
- Economic downturns
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- PHIL
- FSP.NZ
Competitive Landscape
ResMed benefits from its innovative product portfolio and strong brand. However, they face significant competition from Philips (when fully operational again), and Fisher & Paykel. There are a number of other smaller competitors, especially from China. ResMed's SaaS offerings provide a competitive advantage.
Major Acquisitions
Propeller Health
- Year: 2019
- Acquisition Price (USD millions): 225
- Strategic Rationale: Acquired Propeller Health to expand ResMed's digital health offerings and improve patient outcomes through connected health solutions for respiratory diseases like COPD and asthma.
Medifox Dan
- Year: 2022
- Acquisition Price (USD millions): 1000
- Strategic Rationale: Acquired Medifox Dan to expand ResMed's SaaS offerings in Germany and strengthen its position in the out-of-hospital care market.
Growth Trajectory and Initiatives
Historical Growth: ResMed has experienced consistent revenue growth driven by its strong product portfolio and expanding market presence. Growth rates have varied over time depending on market conditions and competitive factors.
Future Projections: Analysts generally project continued revenue growth for ResMed driven by the increasing prevalence of sleep apnea and COPD, and the growing adoption of digital health technologies. Growth rates are subject to change based on market conditions and company performance.
Recent Initiatives: Recent strategic initiatives undertaken by ResMed include acquisitions to expand its SaaS business, investments in R&D to develop new products, and expansion into emerging markets.
Summary
ResMed is a strong company with a leading position in the sleep apnea and respiratory care market. Its innovative product portfolio, SaaS offerings, and global presence are working well. However, ResMed needs to be cautious of competition from Philips, reimbursement policy changes, and potential supply chain disruptions to sustain its growth trajectory.
Peer Comparison
Sources and Disclaimers
Data Sources:
- ResMed Investor Relations
- SEC Filings
- Market Research Reports
- Analyst Estimates
- Company Website
Disclaimers:
This analysis is based on publicly available information and analyst estimates, which are subject to change. This is not financial advice. Consult with a financial professional before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ResMed Inc
Exchange NYSE | Headquaters San Diego, CA, United States | ||
IPO Launch date 1995-06-02 | CEO & Chairman Mr. Michael J. Farrell BE, MBA, SM | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 10600 | Website https://www.resmed.co.in |
Full time employees 10600 | Website https://www.resmed.co.in | ||
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.